Cargando…

Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype

Background: Dolutegravir (DTG)-based first-line regimens have shown superior efficacy versus darunavir (DRV)-based ones in randomized trials. We compared these two strategies in clinical practice, particularly considering the role of pre-treatment drug resistance mutations (DRMs) and of the HIV-1 su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salvo, Pierluigi Francesco, Farinacci, Damiano, Ciccullo, Arturo, Borghi, Vanni, Rusconi, Stefano, Saracino, Annalisa, Gennari, William, Bruzzone, Bianca, Vicenti, Ilaria, Callegaro, Annapaola, Di Biagio, Antonio, Zazzi, Maurizio, Di Giambenedetto, Simona, Borghetti, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059835/ https://www.ncbi.nlm.nih.gov/pubmed/36992471 http://dx.doi.org/10.3390/v15030762

Ejemplares similares

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients
por: Fabbiani, Massimiliano, et al.
Publicado: (2023)

Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice
por: Borghetti, Alberto, et al.
Publicado: (2021)

Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
por: Ciccullo, Arturo, et al.
Publicado: (2019)

Clinical presentation of human monkeypox virus infection during the 2022 outbreak: descriptive case series from a large italian Research Hospital
por: Salvo, Pierluigi Francesco, et al.
Publicado: (2023)

Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study
por: Gagliardini, Roberta, et al.
Publicado: (2018)

Shall We Dance? Extending TANGO’s Results to Clinical Practice
por: Borghetti, Alberto, et al.
Publicado: (2020)

Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen
por: Iannone, Valentina, et al.
Publicado: (2023)

Ventilator-associated pneumonia (VAP) and pleural empyema caused by multidrug-resistant Acinetobacter baumannii in HIV and COVID 19 infected patient: A case report
por: Passerotto, Rosa Anna, et al.
Publicado: (2023)

Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study
por: Lombardi, Francesca, et al.
Publicado: (2023)

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study
por: Rossetti, Barbara, et al.
Publicado: (2019)

Is Dolutegravir Plus Atazanavir Overburdened With Concentration-Related Neurological Events Compared With Other Dual Regimens?
por: Capetti, Amedeo F, et al.
Publicado: (2019)

Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV
por: Donne, Valentina Delle, et al.
Publicado: (2022)

A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen
por: Prosperi, Mattia CF, et al.
Publicado: (2011)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
por: Capetti, Amedeo F., et al.
Publicado: (2017)

Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort
por: Ciccullo, Arturo, et al.
Publicado: (2022)

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
por: Borghetti, Alberto, et al.
Publicado: (2019)

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre
por: Borghetti, Alberto, et al.
Publicado: (2014)

553. A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
por: Verna, John, et al.
Publicado: (2018)

Darunavir-based dual therapy in HIV experienced patients
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
por: Fokam, Joseph, et al.
Publicado: (2020)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
por: Wolf, Eva, et al.
Publicado: (2021)

The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition
por: Delle Donne, Valentina, et al.
Publicado: (2020)

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection
por: Rosso, R, et al.
Publicado: (2009)

Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study
por: Cusato, Jessica, et al.
Publicado: (2022)

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study
por: De Nicolò, Amedeo, et al.
Publicado: (2022)

No evidence of SARS-CoV-2 circulation in HIV-infected patients between December 2019 and February 2020 in Rome, Italy
por: Lombardi, Francesca, et al.
Publicado: (2021)

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014)

Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study
por: Antinori, A, et al.
Publicado: (2019)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial
por: Rossetti, Barbara, et al.
Publicado: (2017)

Implementing a Personalized Antimicrobial Stewardship Program for Women with Gynecological Cancers and Healthcare-Associated Infections
por: Di Giambenedetto, Simona, et al.
Publicado: (2022)

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2017)

1766. Sustained Viral Suppression with Dolutegravir and Boosted Darunavir Dual Therapy Among Highly Treatment-Experienced Individuals
por: Hawkins, Kellie, et al.
Publicado: (2018)

Adequate plasma levels of dolutegravir in combination with ritonavir-boosted darunavir: a pharmacokinetic subgroup analysis of the DUALIS study
por: Weidlich, Simon, et al.
Publicado: (2020)

A novel methodology for large-scale phylogeny partition
por: Prosperi, Mattia C.F., et al.
Publicado: (2011)

A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study)
por: Mussini, Cristina, et al.
Publicado: (2019)

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort
por: Capetti, Amedeo F., et al.
Publicado: (2016)

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2022)

Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016
por: Bellino, S., et al.
Publicado: (2019)

Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients
por: Jabłonowska, Elżbieta, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s4p4qf5gpni1oakpn5i3b9i9f2